American Journal of Psychiatry
July 1, 2004
Ralph Buchert, Rainer Thomasius, Florian Wilke et al.
183 citations
Repeated use of MDMA (ecstasy) may cause long-lasting changes to the brain's serotonin system, but these changes could be reversible over time. Brain scans using PET show reduced availability of serotonin transporters in people who have used MDMA, suggesting damage to serotonin-producing neurons. The study also finds that women are more vulnerable than men to these MDMA-induced alterations. The findings support the idea that MDMA use leads to protracted changes in the serotonergic system, but the reduced serotonin transporter availability might recover with abstinence.
Journal of Psychopharmacology
March 1, 2006
Rainer Thomasius, P. Zapletalova, Kay Uwe Petersen et al.
158 citations
Heavy ecstasy (MDMA) use is associated with lasting verbal memory deficits and elevated psychological symptoms even after more than 2.5 years of abstinence, while reduced serotonin transporter availability in the brain may partially recover when use stops. In a longitudinal study comparing current ecstasy users, ex-users, polydrug controls, and drug-naive controls over two years, ex-users showed the worst verbal memory and highest symptom scores, with no improvement over time. Current users' memory and symptoms did not worsen during continued use. Serotonin transporter availability in the midbrain recovered as current users reduced MDMA use, but this recovery may not reflect neuronal integrity. Pre-existing differences cannot be ruled out as an alternative explanation.
Addiction
July 15, 2005
Rainer Thomasius, Kay Uwe Petersen, P. Zapletalova et al.
54 citations
Current and former ecstasy users show no higher rates of most mental disorders than non-users, except for substance-related disorders. Substance-induced cognitive, affective, and anxiety disorders were more common among ecstasy users than polydrug controls. Lifetime ecstasy dependence occurred in 73% of users. Over half of former users and nearly half of current users met criteria for substance-induced cognitive disorders at testing. Higher lifetime doses of ecstasy predicted cognitive disorders. Pre-existing depression or anxiety did not explain ecstasy use, as these disorders were not more frequent in users. Cognitive problems persisting after more than five months of abstinence may result from MDMA's serotonergic neurotoxicity.
Fortschritte der Neurologie · Psychiatrie
February 1, 1997
Rainer Thomasius, Margit Schmolke, Dana Kraus
Use of MDMA ('Ecstasy') has sharply increased, with changes in the drug scene inside and outside Europe. For some users, Ecstasy leads to abuse of other illegal substances. Since the mid-1980s, at least 48 cases of psychiatric complications have been reported, including acute complications that resolve with intoxication, toxic psychoses, and long-term conditions such as atypical and paranoid psychoses, depression, panic disorders, depersonalization, and behavioral disorders. Convulsive seizures are common central nervous system problems; cerebrovascular accidents and intracranial hemorrhages have also occurred. At least 53 cases of medical complications in MDMA abusers have been reported, 14 of them fatal. Large-scale prospective epidemiological and clinical studies are still lacking.